Citadel Advisors’s Seaport Therapeutics SPTX Stock Holding History

Citadel Advisors’s Portfolio SPTX Stock Details SPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.15M	Buy	+191,144	New	+$3.36M	﹤0.01%	5061

Other funds holding SPTX

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TGV

TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors's SPTX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 191,144 shares worth $4.15M. The stake represents ﹤0.01% of the portfolio and ranks #5061 among its holdings.

53 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

Citadel Advisors held 191,144 shares of Seaport Therapeutics worth $4.15M as of Q2 2026.
Seaport Therapeutics was a new Citadel Advisors position in Q2 2026.
Seaport Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5061 holding.
53 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.